Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: Results of a multicenter randomized clinical trial (Retraction in: Blood (2009) 113:24 (6265))

Blood

Volumn 111, Issue 4, 2008, Pages 1805-1810

  Abdelkefi, Abderrahman ^a   Ladeb, Saloua ^a   Torjman, Lamia ^a   Ben Othman, Tarek ^a   Lakhal, Amel ^a   Ben Romdhane, Neila ^b   El Omri, Halima ^c   Elloumi, Moez ^d   Belaaj, Hatem ^d   Jeddi, Ramzi ^e   Aissaouï, Lamia ^e   Ksouri, Habib ^a   Ben Hassen, Assia ^a   Msadek, Fahmi ^f   Saad, Ali ^c   Hsaïri, Mohamed ^g   Boukef, Kamel ^h   Amouri, Ahlem ⁱ   Louzir, Hechmi ⁱ   Dellagi, Koussay ⁱ   Ben Abdeladhim, Abdeladhim ^a   more..

^a CENTRE NATIONAL DE GREFFE DE MOELLE OSSEUSE   (Tunisia)

^b LA RABTA HOSPITAL   (Tunisia)

^c FARHAT HACHED HOSPITAL   (Tunisia)

^d HEDI CHAKER HOSPITAL   (Tunisia)

^e Hopital Aziza Othmana   (Tunisia)

^f MILITARY HOSPITAL OF TUNIS   (Tunisia)

^g Inst National de la Sante Publique   (Tunisia)

^h Centre National de Transfusion Sanguine Tunis   (Tunisia)

ⁱ PASTEUR INSTITUTE OF TUNIS   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; THALIDOMIDE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME;

EID: 41349095233     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-07-101212     Document Type: Article

References (37)

1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francophone du Myelome. N Engl J Med. 1996;335:91-97.
2. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875-1883.
3. Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007;13:183-196.
4. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495-2502.
5. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25:2434-2441.
6. Tricot G, Jagannath S, Vesole DH, et al. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant. 1995;16:7-11.
7. Mehta J, Tricot G, Jagannath S, et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft. Bone Marrow Transplant. 1998;21:887-892.
8. Kulkarni S, Powles R, Singhal S, et al. Second autografts for relapsed multiple myeloma: is tandem autotransplantation better? Clinical care: recurrence, secondary neoplasia and late complications after transplantation. Blood. 1998;92(suppl 1):344b.
9. Elice F, Raimondi R, Tosetto A, et al. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. Am J Hematol. 2006;81:426-431.
10. Alvares CL, Davies FE, Horton C, et al. The role of second autografts in the management of myeloma at first relapse. Haematologica. 2006;91:141-142.
11. Qazilbash MH, Saliba R, De Lima M, et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer. 2006;106:1084-1089.
12. Morris C, Iacobelli R, Brand B, et al. Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European group for blood and marrow transplantation registry study. J Clin Oncol. 2004;22:1674-1681.
13. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998;92:3131-3136.
14. Sirohi B, Powles R, Singhal S, et al. Second high-dose melphalan autograft for myeloma patients relapsing after one autograft: results equivalent to tandem transplantation. Bone Marrow Transplant. 2002;29(suppl 2):S12.
15. Gertz MA, Lacy MQ, Inwards DJ, et al. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplant. 2000;26:45-50.
16. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007. Epub ahead of print.
17. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
18. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108:3458-3464.
19. Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K. New drugs for myeloma. Oncologist. 2007;12:664-689.
20. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20:4319-4323.
21. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16-19.
22. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106:35-39.
23. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108:3289-3294.
24. Alexanian R, Weber D, Giralt S, Delasalle K. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann Oncol 2002;13:1116-1119.
25. Spencer A, Prince M, Roberts AW, Bradstock KF, Prosser IW. First analysis of the Australasian leukaemia and lymphoma group (ALLG) trial of thalidomide and alternate day prednisolone following autologous stem cell transplantation for patients with multiple myeloma (ALLG MM6) [abstract]. Blood. 2006;108:58a.
26. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated with high-dose therapy and haematopoietic stem cell transplantation. Br J Haematol. 1998;102:1115-1123.
27. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-1473.
28. UK Myeloma Forum, British Committee for Standards in Haematology. Diagnosis and management of multiple myeloma. Br J Haematol. 2001;115:522-540.
29. Abdelkefi A, Torjman L, Ben Romdhane N, et al. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (< 61 years) with symptomatic multiple myeloma. Bone Marrow Transplant. 2005;36:193-198.
30. Munshi NC, Mitsiades CS, Richardson PG, Anderson KC. Does maintenance therapy with thalidomide benefit patients with multiple myeloma? Nat Clin Pract Oncol. 2007. Epub ahead of print.
31. Palumbo A, Bringhen S, Musto P, et al. Oral melphalan, and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet. 2006;367:825-831.
32. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021-1030.
33. El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis: a meta-analysis. Thromb Haemost. 2007;97:1031-1036.
34. Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006;24:4507-4514.
35. Stewart AK, Chen CI, Howson-Jan K, et al. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res. 2004;10:8170-8176.
36. Richardson PG, Schlossman R, Jagannath S, et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc. 2004;79:875-882.
37. Durie BG, Stephan DE. Low dose thalidomide alone and in combination: long term follow-up [abstract]. Blood. 2001;98:163a.